Sinusoidal Obstruction Syndrome during Treatment for Wilms' Tumor: A Life-threatening Complication
- PMID: 29333010
- PMCID: PMC5759062
- DOI: 10.4103/ijmpo.ijmpo_188_16
Sinusoidal Obstruction Syndrome during Treatment for Wilms' Tumor: A Life-threatening Complication
Abstract
Context: Survival rates exceed 90% in Wilms' tumor (WT). Actinomycin-D (ACT-D) which is indispensable in the management of WT is associated with the development of sinusoidal obstruction syndrome (SOS), a potentially fatal complication.
Aims: The aim is to study the presentation, management, and outcome of SOS complicating ACT-D administration in WT.
Settings and design: Retrospective file review conducted in a Pediatric Hematology-Oncology unit.
Materials and methods: Patients diagnosed and treated for WT from January 2012 to December 2015 were analyzed. SOS was diagnosed clinically, based on McDonalds criteria, requiring two of the following: jaundice, hepatomegaly and/or right upper quadrant pain, weight gain with or without ascites.
Results: Of 104 patients treated, SOS occurred in 5 (4.8%). Age: 6 months to 5 years, 3 were girls. Tumor involved left kidney in 3, right in 1 and a horseshoe kidney in 1. Histopathology was consistent with WT in 4 and clear cell sarcoma kidney in 1. One had pulmonary metastases. Three developed SOS preoperatively and two during adjuvant chemotherapy. None received radiotherapy. Clinical manifestations comprised of jaundice, hepatomegaly, ascites/weight gain, respiratory distress, hypotension, and encephalopathy. Laboratory findings included thrombocytopenia, elevated serum transaminases, and coagulopathy. Treatment included fluid restriction, broad spectrum antibiotics, and transfusional support. Two children received N-acetyl cysteine infusion. Defibrotide was administered to two patients. Four recovered and one succumbed to multi-organ failure. Two patients were safely re-challenged with 50% doses of ACT-D.
Conclusions: SOS is a clinical diagnosis. Systematic supportive care can enable complete recovery. Under close monitoring, re-challenge of ACT-D can be performed in gradually escalating doses.
Keywords: Developing country; liver failure; portal hypertension; renal malignancy; veno-occlusive disease.
Conflict of interest statement
There are no conflicts of interest.
Similar articles
-
Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study.Biol Blood Marrow Transplant. 2017 Jun;23(6):997-1004. doi: 10.1016/j.bbmt.2017.03.008. Epub 2017 Mar 8. Biol Blood Marrow Transplant. 2017. PMID: 28285079
-
Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program.Pediatr Blood Cancer. 2018 Oct;65(10):e27269. doi: 10.1002/pbc.27269. Epub 2018 Jun 6. Pediatr Blood Cancer. 2018. PMID: 29873895 Free PMC article. Clinical Trial.
-
Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease after Autologous or Allogeneic Hematopoietic Stem Cell Transplantation in Children: a retrospective study of the Italian Hematology-Oncology Association-Hematopoietic Stem Cell Transplantation Group.Biol Blood Marrow Transplant. 2019 Feb;25(2):313-320. doi: 10.1016/j.bbmt.2018.09.027. Epub 2018 Sep 26. Biol Blood Marrow Transplant. 2019. PMID: 30266674 Clinical Trial.
-
New Ultrasound Techniques Challenge the Diagnosis of Sinusoidal Obstruction Syndrome.Ultrasound Med Biol. 2018 Nov;44(11):2171-2182. doi: 10.1016/j.ultrasmedbio.2018.06.002. Epub 2018 Jul 31. Ultrasound Med Biol. 2018. PMID: 30076031 Review.
-
The use of defibrotide in blood and marrow transplantation.Blood Adv. 2018 Jun 26;2(12):1495-1509. doi: 10.1182/bloodadvances.2017008375. Blood Adv. 2018. PMID: 29945939 Free PMC article. Review.
Cited by
-
Burden of illness of non-hematopoietic stem cell transplant-related hepatic sinusoidal obstruction syndrome: A systematic review.Heliyon. 2024 Aug 31;10(20):e36883. doi: 10.1016/j.heliyon.2024.e36883. eCollection 2024 Oct 30. Heliyon. 2024. PMID: 39640784 Free PMC article. Review.
-
Drug-induced hepatic sinusoidal obstruction syndrome: current advances and future perspectives.Arch Toxicol. 2025 Mar;99(3):835-850. doi: 10.1007/s00204-024-03950-9. Epub 2024 Dec 24. Arch Toxicol. 2025. PMID: 39718593 Review.
References
-
- PDQ Cancer Information Summaries. Bethesda (MD): National Cancer Institute (US); 2002. [Last accessed on 2016 Aug 11]. PDQ Pediatric Treatment Editorial Board. Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®): Health Professional Version. Available from: http://www.ncbi.nlm.nih.gov/books/NBK65842/ - PubMed
-
- Hopps SA, Borders EB, Hagemann TM. Prophylaxis and treatment recommendations for sinusoidal obstruction syndrome in adult and pediatric patients undergoing hematopoietic stem cell transplant: A review of the literature. J Oncol Pharm Pract. 2016;22:496–510. - PubMed
-
- Cesaro S, Spiller M, Sartori MT, Alaggio R, Peruzzo M, Saggiorato G, et al. Veno-occlusive disease in pediatric patients affected by Wilms tumor. Pediatr Blood Cancer. 2011;57:258–61. - PubMed
-
- Czauderna P, Katski K, Kowalczyk J, Kurylak A, Lopatka B, Skotnicka-Klonowicz G, et al. Venoocclusive liver disease (VOD) as a complication of Wilms' tumour management in the series of consecutive 206 patients. Eur J Pediatr Surg. 2000;10:300–3. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources